Novo Nordisk A/S
The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will get one of the following: Zenagamtide (the treatment being tested) or Semaglutide (an approved and commonly prescribed treatment used as comparator).
Inclusion Criteria: * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18 years or above at the time of signing the informed consent. * Diagnosed with type 2 diabetes (T2D) above or equal to 180 days before screening. * On stable daily dose(s) of metformin, sodium-glucose transport 2 (SGLT2) inhibitor, or both (at effective or maximum tolerated dose as judged by the investigator) prior to screening. * Glycated haemoglobin (HbA1c) as determined by central laboratory at screening. Exclusion Criteria: * Female who is pregnant, breast-feeding or intends to becom…
Zenagamtide will be administered subcutaneously
Semaglutide will be administered subcutaneously
Placebo matched to semaglutide or zenagamtide will be administered subcutaneously